Literature DB >> 1333261

On the interpretation of proton NMR spectra from brain tumours in vivo and in vitro.

H Bruhn1, T Michaelis, K D Merboldt, W Hänicke, M L Gyngell, C Hamburger, J Frahm.   

Abstract

Localized proton NMR spectroscopy in vivo allows focal studies of cerebral metabolites in both man and laboratory animals from image-defined regions as small as 1 mL or 64 microL, respectively. Although brain tumours lead to remarkable spectral alterations relative to normal brain, a number of problems may compromise the interpretation of the results. Potential complications arise from the chosen experimental conditions (method, TE, size and location of volume of interest), from regional metabolic heterogeneity in and around tumours, from differences between human tumours and animal models, and from discrepancies between in vivo and in vitro findings. Strategies and pitfalls are illustrated with use of selected examples from primary brain tumours, a rat tumour model and perchloric acid extracts of resected specimens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1333261     DOI: 10.1002/nbm.1940050510

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  12 in total

1.  Localized proton magnetic resonance spectroscopy of a cerebellar tumor in a two-year-old child.

Authors:  B Wilken; G Helms; H J Christen; J Behnke; J Frahm; F Hanefeld
Journal:  Childs Nerv Syst       Date:  1996-10       Impact factor: 1.475

2.  Proton magnetic resonance spectroscopy and intracranial tumours: clinical perspectives.

Authors:  A Falini; G Calabrese; D Origgi; S Lipari; F Triulzi; M Losa; G Scotti
Journal:  J Neurol       Date:  1996-10       Impact factor: 4.849

3.  Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy.

Authors:  F Federico; I L Simone; V Lucivero; M De Mari; P Giannini; G Iliceto; D M Mezzapesa; P Lamberti
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

4.  Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors.

Authors:  A Lin; S Bluml; A N Mamelak
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

5.  123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study.

Authors:  Michail Plotkin; Julia Eisenacher; Harald Bruhn; Reinhard Wurm; Roger Michel; Florian Stockhammer; Annelie Feussner; Oliver Dudeck; Peter Wust; Roland Felix; Holger Amthauer
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

6.  MR spectroscopy in gliomatosis cerebri.

Authors:  M Bendszus; M Warmuth-Metz; R Klein; R Burger; C Schichor; J C Tonn; L Solymosi
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

7.  Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases.

Authors:  Tomoo Inoue; Toshihiro Kumabe; Masayuki Kanamori; Yukihiko Sonoda; Mika Watanabe; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2011-02-08       Impact factor: 3.042

8.  Measurement of glycine in the human brain in vivo by 1H-MRS at 3 T: application in brain tumors.

Authors:  Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Ivan E Dimitrov; Juan M Pascual; Robert Bachoo; Bruce E Mickey; Craig R Malloy; Elizabeth A Maher
Journal:  Magn Reson Med       Date:  2011-03-09       Impact factor: 4.668

Review 9.  What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy?

Authors:  J Vion-Dury; D J Meyerhoff; P J Cozzone; M W Weiner
Journal:  J Neurol       Date:  1994-05       Impact factor: 4.849

10.  A rare case of gliomatosis cerebri presenting as dementia.

Authors:  Manish Gutch; M K Ansari; Nirdesh Jain; Himanshu Yadav
Journal:  J Nat Sci Biol Med       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.